RETRACTED: Novel insights into rosacea's role in cancer risk: A Mendelian randomization approach
Skin Research and Technology · 2024
DOI: 10.1111/srt.13737 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift Skin Research and Technology, 2024. Verfasst von Mao Luo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Rosacea, Mendelian Randomization Analysis, Polymorphism, Single Nucleotide, Skin Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chongqing science and health joint medical scientific research, Chongqing natural science foundation project.
Abstract (Originalsprache)
Background
Chronic inflammation has been shown to promote cancer progression. Rosacea is indeed a long‐term inflammatory skin condition and had been reported to link with increased risk for several types of malignancies, but evidence for causality is lacking.
Objectives
To systematically estimate the causal relationship between rosacea and several types of cancer, including cutaneous malignant melanoma (CMM), cutaneous squamous cell carcinoma (cSCC), basal cell carcinoma (BCC), actinic keratosis (AK), thyroid cancer, breast cancer, glioma and hepatic cancer, as well as explore the potential underlying pathogenesis.
Methods
We conducted a bidirectional two‐sample Mendelian randomization study to probe the potential causal relationships between rosacea and several types of cancer. Instrumental variables were established using genome‐wide significant single nucleotide polymorphisms associated with rosacea and cancers. The assessment of causality was carried out through multiple methods, and the robustness of the results was evaluated via sensitivity analyses.
Results
There was no significant indication of causal effects of rosacea on CMM ( p ivw = 0.71), cSCC ( p ivw = 0.45), BCC ( p ivw = 0.90), AK ( p ivw = 0.73), thyroid cancer ( p ivw = 0.59), glioma ( p ivw = 0.15), and hepatic cancer ( p ivw = 0.07), but the genetic risk of rosacea was associated with an increased susceptibility to human epidermal growth factor receptor (HER)‐negative malignant neoplasm of breast (odds ratio [OR], 1.10; 95% confidence interval [CI], 1.02–1.18; p ivw = 0.01). TANK (TRAF family member associated nuclear factor kappa B (NFKB) activator) was identified as a common protective gene for both rosacea (OR, 0.90; 95% CI, 0.82–0.99; p ivw = 0.048) and HER‐negative malignant neoplasm of the breast (OR, 0.86; 95% CI, 0.75–0.98; p ivw = 0.032), which was primarily enriched in the negative regulation of NF‐κB signal transduction and may contribute to the genetic links between rosacea and this subtype of breast cancer.
Conclusions
Our findings provide suggestive evidence for causal links between rosacea and HER‐negative malignant neoplasm of the breast risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University Yubei Hospital (Yubei District People's Hospital of Chongqing), Chongqing, China.
Förderung
- Chongqing science and health joint medical scientific research
- Chongqing natural science foundation project
Zitieren
APA
Luo, M., & Wei, B. (2024). RETRACTED: Novel insights into rosacea's role in cancer risk: A Mendelian randomization approach. Skin Research and Technology. https://doi.org/10.1111/srt.13737
Vancouver
Luo M, Wei B. RETRACTED: Novel insights into rosacea's role in cancer risk: A Mendelian randomization approach. Skin Research and Technology. 2024. doi:10.1111/srt.13737
BibTeX
@article{Luo2024,
author = {Luo, Mao and Wei, Bin},
title = {RETRACTED: Novel insights into rosacea's role in cancer risk: A Mendelian randomization approach},
journal = {Skin Research and Technology},
year = {2024},
doi = {10.1111/srt.13737}
}
EUVIMED